©2024 Stanford Medicine
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Not Recruiting
Trial ID: NCT04508725
Purpose
To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of
treatment, as measured by power Doppler ultrasound, can predict initial objective response,
defined by current standard-of-care, to therapy at 12 weeks after start of treatment
Official Title
Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Stanford Investigator(s)
Alice C. Fan
Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology
Aya Kamaya, MD
Professor of Radiology (Body Imaging)
Ali Raza Khaki, MD
Clinical Assistant Professor, Medicine - Oncology
Eligibility
Inclusion Criteria:
- 18 years of age or older
- Pathology-confirmed diagnosis of metastatic RCC
- At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound
imaging
- Written informed consent.
Specific inclusion criteria:
- arm 1: planned to be treated with combination of VEGFR2 tyrosine kinase inhibitor
(TKI) plus immune checkpoint inhibitor (ICI)
- arm 2: planned to be treated with non-ICI therapy
Exclusion Criteria:
-Any comorbid condition that, in the opinion of the treating provider or the Protocol
Directors, compromises the participant's ability to participate in the study
Intervention(s):
diagnostic test: Doppler Ultrasound
device: SIEMENS S3000 and Verasonics Vantage 256
drug: Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor plus immune checkpoint inhibitor
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Christian Hoerner, PhD
650-721-3206